Lipid Lowering Oxopropanylindole Hydrazone Derivatives with Antioxidant and Anti-hyperglycemic Activity.
A series of substituted oxopropanylindole hydrazone derivatives was synthesized and evaluated for anti-oxidant and anti-dyslipidemic activity. Of the 12 tested, 3 compounds (6c, 7b and 7d) showed good anti-oxidant activity, compound 6c attenuated LDL oxidation by 32%. The compounds 6c and 7d also showed good anti-dyslipidemic activity by reducing serum levels of total cholesterol (TC), phospholipids (PL) and triglycerides (TG). These two compounds were further evaluated for antiadipogenic and anti-hyperglycemic activity, where 6c showed 44% reduction in lipid accumulation and 20.5% and 24.3% reduction in blood glucose at 5h and 24h respectively, as compared to standard drug metformin. Thus, compounds 6c and 7d with balanced anti-oxidant and anti-dyslipidimic activities may be excellent candidates for lead optimization and drug development for the treatment of metabolic disorders.
['Varshney|Kanika|K|', 'Gupta|Amit K|AK|', 'Sonkar|Ravi|R|', 'Varshney|Salil|S|', 'Mishra|Akanksha|A|', 'Bhatia|Geetika|G|', 'Gaikwad|Anil|A|', 'Srivastava|Arvind Kumar|AK|', 'Saxena|Mridula|M|', 'Jain|Sudha|S|', 'Saxena|Anil K|AK|']
D041721:3T3-L1 Cells D000818:Animals D000975:Antioxidants D001786:Blood Glucose D002478:Cells, Cultured D006801:Humans D006835:Hydrazones D017665:Hydroxyl Radical D007004:Hypoglycemic Agents D007211:Indoles D008077:Lipoproteins, LDL D008297:Male D051379:Mice D010100:Oxygen D051381:Rats D017207:Rats, Sprague-Dawley
Hydrazone derivatives Anti-hyperglycemic Anti-oxidant Anti-dyslipidemic Atherosclerosis Lipid.